Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis

Rheumatology (United Kingdom)

Volumn 58, Issue , 2019, Pages i17-i26

  Taylor, Peter C ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

baricitinib; efficacy; function; Janus kinase; patient reported outcomes; rheumatoid arthritis; small molecule kinase inhibitor; structural damage; symptoms and signs; tofacitinib

Indexed keywords

BARICITINIB; JANUS KINASE INHIBITOR; METHOTREXATE; TOFACITINIB; ANTIRHEUMATIC AGENT; AZETIDINE DERIVATIVE; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SULFONAMIDE;

ARTICLE; CLINICAL EFFECTIVENESS; DRUG SAFETY; EUROPEAN MEDICINES AGENCY; HUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; COMBINATION DRUG THERAPY; TREATMENT OUTCOME;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AZETIDINES; DRUG THERAPY, COMBINATION; HUMANS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; JANUS KINASE INHIBITORS; METHOTREXATE; PIPERIDINES; PYRIMIDINES; PYRROLES; SULFONAMIDES; TREATMENT OUTCOME;

EID: 85062187920     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/key225     Document Type: Article

References (47)

1. Smolen JS, Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015;11:276-89.
2. Singh JA, Saag KG, Bridges SL Jr et al. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res 2016;68:1-25.
3. Smolen JS, Landewe R, Bijlsma J et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 2017;76:960-77.
4. Smolen JS, Breedveld FC, Burmester GR et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis 2016;75:3-15.
5. Taylor PC, Moore A, Vasilescu R, Alvir J, Tarallo M. A structured literature review of the burden of illness and unmet needs in patients with rheumatoid arthritis: a current perspective. Rheumatol Int 2016;36:685-95.
6. Migita K, Izumi Y, Torigoshi T et al. Inhibition of Janus kinase/signal transducer and activator of transcription (JAK/STAT) signalling pathway in rheumatoid synovial fibroblasts using small molecule compounds. Clin Exp Immunol 2013;174:356-63.
7. Walker JG, Ahern MJ, Coleman M et al. Changes in synovial tissue Jak-STAT expression in rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006;65:1558-64.
8. Walker JG, Ahern MJ, Coleman M et al. Expression of Jak3, STAT1, STAT4, and STAT6 in inflammatory arthritis: unique JAK3 and STAT4 expression in dendritic cells in seropositive rheumatoid arthritis. Ann Rheum Dis 2006;65:149-56.
9. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem 2014;57:5023-38.
10. Burmester GR, Blanco R, Charles-Schoeman C et al. Tofacitinib (CP-690, 550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial. Lancet 2013;381:451-60.
11. Fleischmann R, Kremer J, Cush J et al. Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. N Engl J Med 2012;367:495-507.
12. Kremer J, Li ZG, Hall S et al. Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trial. Ann Internal Med 2013;159:253-61.
13. Lee YCE, Emery P, Bradley JD et al. Remaining pain in DMARD-naive rheumatoid arthritis patients treated with baricitinib and methotrexate [abstract]. Arthritis Rheumatol 2017;69(Suppl 10):https://acrabstracts.org/ abstract/remaining-pain-in-dmard-naive-rheumatoid-arthritis- patients-treated-with-baricitinib-and-methotrexate/ (date last accessed 26 July 2018).
14. van der Heijde D, Tanaka Y, Fleischmann R et al. Tofacitinib (CP-690, 550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013;65:559-70.
15. van Vollenhoven RF, Fleischmann R, Cohen S et al. Tofacitinib or adalimumab versus placebo in rheumatoid arthritis. N Engl J Med 2012;367:508-19.
16. Fridman JS, Scherle PA, Collins R et al. Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050. J Immunol 2010;184:5298-307.
17. Dougados M, van der Heijde D, Chen YC et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis 2017;76:88-95.
18. Fleischmann R, Schiff M, van der Heijde D et al. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited prior disease-modifying antirheumatic drug treatment. Arthritis Rheum 2017;69:506-17.
19. Genovese MC, Kremer J, Zamani O et al. Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 2016;374:1243-52.
20. Taylor PC, Keystone EC, van der Heijde D et al. Baricitinib versus placebo or adalimumab in rheumatoid arthritis. N Engl J Med 2017;376:652-62.
21. Westhovens R. Clinical efficacy of JAK inhibitors under development. Just more of the same? Rheumatology 2019;58:i27-i33.
22. Yamaoka K. Janus kinase inhibitors for rheumatoid arthritis. Curr Opin Chem Biol 2016;32:29-33.
23. Fleischmann RM, Huizinga TW, Kavanaugh AF et al. Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis. RMD Open 2016;2:e000262.
24. Traynor K. FDA approves tofacitinib for rheumatoid arthritis. Am J Health Syst Pharm 2012;69:2120.
25. Lamba M, Wang R, Fletcher T et al. Extended-release once-daily formulation of tofacitinib: evaluation of pharmacokinetics compared with immediate-release tofacitinib and impact of food. J Clin Pharm 2016;56:1362-71.
26. Strand V, Lee EB, Fleischmann R et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open 2016;2:e000308.
27. Fleischmann R, Mysler E, Hall S et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet 2017;390:457-68.
28. Strand V, Kremer J, Wallenstein G et al. Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs. Arthritis Res Ther 2015;17:307.
29. Strand V, van Vollenhoven RF, Lee EB et al. Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis. Rheumatol 2016;55:1031-41.
30. Strand V, Kremer JM, Gruben D et al. Tofacitinib in combination with conventional disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: patient-reported outcomes from a phase III randomized controlled trial. Arthritis Care Res 2017;69:592-8.
31. Strand V, Burmester GR, Zerbini CA et al. Tofacitinib with methotrexate in third-line treatment of patients with active rheumatoid arthritis: patient-reported outcomes from a phase III trial. Arthritis Care Res 2015;67:475-83.
32. Lee EB, Fleischmann R, Hall S et al. Tofacitinib versus methotrexate in rheumatoid arthritis. N Engl J Med 2014;370:2377-86.
33. Richez C, Truchetet ME, Kostine M, Schaeverbeke T, Bannwarth B. Efficacy of baricitinib in the treatment of rheumatoid arthritis. Expert Opin Pharmacother 2017;18:1399-407.
34. Takeuchi T, Genovese M, Xie LI, et al. Baricitinib dose stepdown following disease control in patients with rheumatoid arthritis. Ann Rheum Dis 2016;75(Suppl 2):144.
35. Keystone EC, Taylor PC, Tanaka Y et al. Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study. Ann Rheum Dis 2017;76:1853-61.
36. Smolen JS, Kremer JM, Gaich CL et al. Patient-reported outcomes from a randomised phase III study of baricitinib in patients with rheumatoid arthritis and an inadequate response to biological agents (RA-BEACON). Ann Rheum Dis 2017;76:694-700.
37. Harigai M. Growing evidence of the safety of JAK inhibitors in patients with rheumatoid arthritis. Rheumatology 2019;58:i34-i42.
38. Schulze-Koops H, Strand V, Nduaka C et al. Analysis of haematological changes in tofacitinib-treated patients with rheumatoid arthritis across phase 3 and long-term extension studies. Rheumatol 2017;56:46-57.
39. Kay J, Harigai M, Rancourt J et al. Effects of baricitinib on haemoglobin and related laboratory parameters in rheumatoid arthritis patients. Ann Rheum Dis 2017;76(Suppl 2):513-4.
40. Emery P, McInnes I, Genovese M et al. Characterisation of changes in lymphocyte subsets in baricitinib-treated patients with rheumatoid arthritis in two phase 3 studies. Ann Rheum Dis 2016;75(Suppl 1):A62-A.
41. van Vollenhoven RF, Tanaka Y, Lamba M et al. Relationship between NK cell count and important safety events in rheumatoid arthritis patients treated with tofacitinib. Ann Rheum Dis 2015;74(Suppl 2):258-9.
42. McInnes IB, Kim HY, Lee SH et al. Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study. Ann Rheum Dis 2014;73:124-31.
43. Kremer JM, Genovese MC, Keystone E et al. Effects of baricitinib on lipid, apolipoprotein, and lipoprotein particle profiles in a phase IIb study of patients with active rheumatoid arthritis. Arthritis Rheum 2017;69:943-52.
44. Charles-Schoeman C, Wicker P, Gonzalez-Gay MA et al. Cardiovascular safety findings in patients with rheumatoid arthritis treated with tofacitinib, an oral Janus kinase inhibitor. Semin Arthritis Rheum 2016;46:261-71.
45. Taylor PC, Kremer J, Emery P et al. Lipid profile and effect of statin treatment in pooled phase 2 and phase 3 baricitinib studies. Ann Rheum Dis 2018;77:988-995.
46. Breedveld FC, Weisman MH, Kavanaugh AF et al. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006;54:26-37.
47. van Vollenhoven RF, Ernestam S, Geborek P et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. Lancet 2009;374:459-66.